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Abstract
Isocitrate dehydrogenase (IDH) mutation is one of the most critical genomic 
alterations in lower grade and secondary glioblastoma patient. More than 90% of 
IDH mutation is located at codon R132 of IDH1 gene. IDH mutation produces onco-
metabolite “2-hydroxyglutarate” and induces epigenetic alteration, such as DNA 
global methylation and histone methylation. As a result, IDH mutation promotes 
early gliomagenesis. Since IDH mutation is the earliest genomic event and almost 
always retained during tumor progression, IDH mutation is expected as novel 
therapeutic target. Herein, we review the clinical characteristics of IDH-mutant 
gliomas, biological role of IDH mutation for gliomagenesis, and current and future 
therapeutic approach for IDH mutant tumors.
Keywords: IDH mutation, glioma, 2-hydroxyglutarate, tumor biology, 
cancer metabolism, target therapy
1. Introduction
The WHO 2016 classification integrates molecular and histological features 
in the diagnosis of gliomas. Among numerous genomic alterations, the isocitrate 
dehydrogenase (IDH) mutation is one of the most important genetic alterations 
found in this kind of tumor. As IDH mutation is a ubiquitous mutation in lower 
grade gliomas, the development of molecular target therapies against IDH muta-
tions is expected. Here, we review IDH-mutant gliomas, focusing on their role in 
tumorigenesis and as novel therapeutic targets.
2. Discovery of IDH mutations in cancers
The presence of an isocitrate dehydrogenase (IDH) mutation was first discovered 
in colorectal cancers [1]. Parsons et al. [2] found mutations of the IDH1 (2q.33) in 
12% of the glioblastomas (GBMs). Other large scale studies validated that IDH1 
and IDH2 (IDH) mutations were found in the majority of secondary GBM and 
lower grade (WHO grade II and III) gliomas, whereas these were rarely found in 
adult primary and pediatric GBMs [2–4]. Almost all of the IDH1 mutations occur 
at codon 132, >90% of them exhibit a c.395G>A (R132H) substitution, followed by 
R132C [3, 5, 6]. Although the frequency was low, IDH2 mutations were also identi-
fied at codon 172 in gliomas [4, 7].
Besides, IDH mutation was found in hematopoietic cancers, including acute 
myeloid leukemia (AML; 10–15%, IDH2) [8, 9], angioimmunoblastic T-cell lym-
phoma (AITL, 20%) [10], chondrosarcoma (~50%) [11–13], intrahepatic cholan-
giocarcinoma (15–20%, IDH1) [13], and at lower frequency in other hematopoietic 
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and solid cancers, such as B-acute lymphoblastic leukemia (B-ALL), esophageal 
cancer, colorectal cancer, melanoma, prostate carcinoma, and breast adenocarci-
noma [1, 4, 14–16].
3. Tumorigenesis of IDH-mutant gliomas
3.1 Genomic characteristics of IDH-mutant glioma
The discovery of IDH mutations allowed the distinction of primary GBM, 
which is genetically characterized by TERT promoter mutation, gene alteration 
of epidermal growth factor receptor (EGFR), phosphatase and tensin homolog 
(PTEN) mutation or deletion, trisomy 7, monosomy 10, and cyclin-dependent 
kinase inhibitor 2A (CDKN2A) homozygous deletion, from secondary GBM (GBM, 
IDH-mutant) [3, 5, 17, 18].
In astrocytic tumors, most of the tumor cells have co-mutations in IDH1, TP53, 
and ATRX. Moreover, WHO 2016 [19] defined the presence of IDH mutation and co-
deletion of chromosome1p and 19q as necessary for the diagnosis of oligodendroglial 
tumors. Also, in oligodendroglial tumors, TERT promoter mutation is almost always 
present (>95%), while CIC and FUBP1 are commonly (>40%) observed. These 
genetic abnormalities for astrocytic and oligodendroglial tumors are mutually 
exclusive [20–24]. Importantly, the IDH mutation is the earliest genetic alteration 
observed; it is commonly retained during tumor progression [25–28], but in a subset 
of mutants, IDH1 was either deleted or amplified at tumor recurrence [29], indicat-
ing the critical role of IDH mutation for tumorigenesis. It has also been shown that 
IDH mutations do not select or create ATRX or TERT promoter mutations [30].
3.2 Developmental hierarchy in IDH-mutant gliomas
Two recent large scale single cell RNA-sequencing studies revealed a devel-
opmental hierarchy in IDH1-mutant gliomas [31, 32]. Accordingly, IDH1-mutant 
astrocytoma and oligodendroglioma shared a similar developmental hierarchy, 
consisting of three subpopulations of malignant cells: nonproliferative astrocytic 
and oligodendrocytic cells, proliferative, and undifferentiated neural stem/progeni-
tor cells. In contrast, tumor micro environment (TME) was different in the abun-
dance microglia/macrophage cells between astrocytic and oligodendroglial tumors. 
TME also differs between astrocytic tumors of different grades. Though TME and 
genomic alterations are distinctive, evidence indicates the existence of common 
progenitor cells in IDH1-mutant gliomas. In higher grade tumors, undifferentiated 
glioma stem/progenitor cells were increased [32]. In addition, almost all proliferat-
ing cancer cells were composed of subpopulations of undifferentiated cells (stem-
like) in oligodendroglioma [31], suggesting a significant role for undifferentiated 
cells in cell proliferation and malignant progression.
3.3 IDH-mutant xenograft model
Although IDH1 mutation induced proliferation in vitro [33], IDH1 mutation did 
not promote xenograft formation [34–36]. Intriguingly, Bardella et al. [37] demon-
strated that IDH1R132H overexpression in the murine subventricular zone induced the 
formation of early gliomagenesis, where stem and transit amplifying/progenitor cell 
populations were expanded, indicating the pivotal role of IDH1 mutation in glioma 
formation. Moreover, Wakimoto et al. demonstrated that “tertiary mutations,” such 
as PIK3CA mutation, PDGFRA amplification, and MYC amplification, promote 
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IDH1-mutant glioma formation in xenograft models. Importantly, tumor harboring 
tertiary mutations were associated with unfavorable prognosis in IDH1-mutant glioma 
patients [38]. Recently, large genomic analyses demonstrated that malignant progres-
sion in IDH1-mutant glioma is associated with the PI3K pathway and MYC activation 
[39, 40]. Thus, IDH mutation induces gliomagenesis, whereas tertiary mutations are 
critical to promote tumor progression in lower grade gliomas (Figure 1).
4. The 2016 WHO classification
The 2016 World Health Organization (WHO) Classification of Tumors of the 
Central Nervous System (CNS) integrated phenotypic and genotypic parameters 
for CNS tumor classification. According to this classification, all diffusely infiltrat-
ing gliomas are grouped as diffuse astrocytic and oligodendroglial tumors. These 
tumors were histologically and genetically classified based on the presence of IDH 
mutation, co-deletion of chromosome1p and 19q, or ATRX and TP53 mutations. 
Accordingly, gliomas are classified as follows: (1) diffuse astrocytoma (WHO grade 
II) or anaplastic astrocytoma (AA, WHO grade III): IDH-mutant, -wildtype, or not 
otherwise specified (NOS); (2) oligodendroglioma (WHO grade II) or anaplastic 
oligodendroglioma (WHO grade III): IDH-mutant and 1p/19q-codeleted or NOS; 
(3) oligoastrocytoma (grade II) and anaplastic oligoastrocytoma (WHO grade III): 
NOS; (4) GBM (WHO grade IV): IDH-mutant, -wildtype, or NOS; and (5) diffuse 
midline glioma (WHO grade IV): H3K27M-mutant.
IDH-wildtype GBM (about 90% of cases) is known as primary GBM, while 
IDH-mutant GBM (about 10% of cases) corresponds to secondary GBM [19].
5. Epidemiology of IDH-mutant gliomas
5.1 Age distribution of IDH-mutant gliomas
According to some statistical analyses, the IDH-mutant GBM or anaplas-
tic astrocytoma patients were more than 20 years younger than those with 
Figure 1. 
Genomic alteration and tumor microenvironment in IDH-mutant astrocytic and oligodendroglial tumors.
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IDH-wildtype GBM [4]. In contrast, IDH-mutant GBM patients were only 4 years 
older than those with IDH1-mutant grade II and III astrocytoma [41]. This indicates 
that IDH-mutant glioma arises earlier than IDH-wildtype glioma (mostly GBM).
5.2 Prognosis of IDH-mutant gliomas
Parsons et al. [2] initially demonstrated that IDH1-mutant GBM patients 
survived about threefold longer than those with IDH1-wildtype GBM. Other groups 
verified that IDH1 mutation is a favorable prognostic biomarker in gliomas  
[4, 42, 43]. In addition to GBM, large amounts of clinical studies indicated that the 
IDH mutation was an independent prognostic factor in grade II and III gliomas [ 
4, 28, 43–47]. Notably, the prognosis of IDH1-mutant GBM is better than of IDH1-
wildtype AA [48]. Also, a prospective randomized study (NOA-04) revealed that 
IDH1 mutation, hypermethylation of the O6-methylguanine DNA-methyltransferase 
(MGMT) promoter, age, extent of resection, and oligodendroglial histology are 
independent prognostic factors in anaplastic gliomas [44]. Among them, the impact 
of IDH1 mutation conferred a stronger favorable prognosis than 1p/19q co-deletion, 
MGMT promoter methylation, and histology [44]. Collectively, IDH1 mutation is a 
convincing prognostic factor in gliomas, irrespective of tumor grade and histology.
5.3 Prognostic classification for gliomas
Suzuki et al. [28] distinguished lower grade gliomas on the basis of the presence 
of IDH1 mutation, TP53 mutation, and 1p/19q co-deletion. Accordingly, tumors 
were classified into three groups: type I (IDH1-mutant with 1p/19q co-deletion; 
favorable prognostic group), type II (IDH1-mutant with TP53 mutation; intermedi-
ate prognostic group), and type III (IDH1-wildtype; poor prognostic group). Eckel-
Passow et al. [47] classified gliomas into five groups based on the mutation status of 
IDH1 and TERT promoter and on 1p/19q co-deletion. This group also demonstrated 
that TERT promoter mutations and ATRX alterations provided additional informa-
tion for a tailored prognostic classification [49]. Besides, Arita et al. [50] proposed a 
classification of grade II–IV gliomas based on the mutations in IDH and the hotspot 
in TERT promoter.
Among IDH-mutant astrocytic tumors, CDKN2A/B homozygous deletion was 
demonstrated to be an unfavorable prognostic molecular marker [51]. Similarly, 
another group demonstrated that PIK3R1 mutation and altered retinoblastoma 
pathway genes, including RB1 and CDKN2A, were independent predictors of poor 
survival in astrocytic tumors. In oligodendrogliomas, NOTCH pathway inactiva-
tion and PI3K pathway activation were associated with poor prognosis [52, 53]. 
Collectively, these molecular markers could predict prognosis in glioma patients.
6. The mechanism of tumorigenesis in IDH1-mutant gliomas
6.1 IDH mutation drives production of oncometabolite D-2-hydroxyglutarate
In humans, IDH is composed of three types of isozymes (IDH1, IDH2, and 
IDH3). IDH1 is located in the cytoplasm and peroxisomes, whereas IDH2 and IDH3 
are localized in the mitochondria and are involved in the TCA cycle. IDH1 and IDH2 
are NADP+ dependent, whereas IDH3 is NAD+ dependent. IDH converts isocitrate 
into α-ketoglutarate (α-KG). No mutation in IDH3 has been detected in human 
cancers. If IDH is mutated, it blocks normal enzymatic activity and instead pro-
duces D-2-hydroxyglutarate (2-HG) from α-KG in an NADPH dependent manner, 
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irrespective of the substituted amino acid [54–56]. Compared with IDH-wildtype 
cells, the 2-HG level in IDH-mutant cells is 50–100-fold higher [54, 57]. IDH muta-
tions are almost always heterozygous, and both mutant and wildtype IDH1 alleles 
are required for 2-HG production in glioma cells [58].
6.2 IDH-mutation induced epigenetic alterations
6.2.1 IDH-mutation inducible DNA hypermethylator phenotype
Since the structure of 2-HG is similar to that of α-KG, 2-HG inhibits a variety 
of α-KG-dependent dioxygenases [59, 60]. Among them, 10–11 translocation-2 
(TET2) induces global demethylation of DNA by catalyzing the conversion of 
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC). Forced mutant 
IDH1 caused increased 5mC concentrations, instead of decreased 5hmC [37, 61]. 
IDH mutation also promotes methylation of DNA by TET2 inhibition, resulting in 
a glioma CpG island methylator phenotype (G-CIMP), a specific DNA methyla-
tion pattern in IDH-mutant tumor cells [61–63]. Indeed, forced overexpression 
of mutant IDH (IDH1R132H and IDH2R172K) produced high concentrations of 2-HG 
and increased global 5-mC levels [61]. Similarly, TET2 mutations, which are 
mutually exclusive to IDH mutations, induce a global hypermethylation signature 
[61]. Turcan et al. [64] demonstrated that a G-CIMP-like phenotype and G-CIMP 
positive proneural glioblastomas were formed after the introduction of an IDH1 
mutation into normal human astrocytes (NHA). These data indicate that mutant 
IDH induced TET2 suppression, followed by G-CIMP, in cancer cells. Consistent 
with IDH-mutant glioma patients, glioma patients with G-CIMP are younger at 
diagnosis and survive longer than those without G-CIMP [62]. Intriguingly, about 
10% of G-CIMP tumors were relapsed as G-CIMP low tumors with poor clinical 
outcome [65].
The Cancer Genome Atlas (TCGA) performed comprehensive transcriptome 
analysis. Accordingly, GBM was classified into four groups (classic, mesenchymal, 
proneural, and neural groups). Aberrations and gene expression of EGFR and 
NF1 define the classical and mesenchymal subtypes, whereas tumors with an 
IDH1 mutation were classified within the proneural group. The proneural group is 
also accompanied by a PDGFRA gene abnormality and the G-CIMP feature [66]. 
DNA methylation induced by the IDH1 mutation caused hypermethylation at 
cohesion and CCCTC-binding factor (CTCF) binding sites and compromised the 
binding of the insulator protein. As a result, loss of CTCF at a domain permits a 
constitutive enhancer to interact aberrantly with the receptor tyrosine kinase gene 
PDGFRA [67].
6.2.2 IDH mutation promotes global histone methylation
IDH mutation is also known to increase histone methylation. Lysine methyla-
tion of histone tails modifies chromatin structure and regulates gene expression. 
By competition with α-KG, 2-HG inhibits histone demethylases including mem-
bers of the Jumonji transcription factor family (JMJD2A, JMJD2C/KDM4C, and 
JHDM1A/FBXL11), resulting in histone hypermethylation [68]. Indeed, 
hypermethylation in H3K4me1, H3K4me3, H3K9me2, H3K27me2, H3K79me2, 
H3K27me3, H3K9me3, and H3K36me3 was observed in cells with exogenous 2-HG 
or mutant IDH1 induction [60, 63, 64, 69]. Sasaki et al. [63] also demonstrated 
that IDH1R132H knock in mice showed significantly increased early hematopoietic 
progenitors, histone hypermethylation, and DNA methylation. Interestingly, 
the elevation of H3K9me3 levels was observed earlier than the DNA methylation 
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change in NHA upon IDH1R132H induction [69], suggesting that histone meth-
ylation may be an early event in IDH1-mutant cancers. The hypermethylation 
of histones blocks cell differentiation in cancer cells [60, 63, 64, 69]. Using a 
histone demethylating agent or a specific mutant IDH1 inhibitor, suppressed cell 
differentiation can be restored [70, 71]. Besides, 2-HG impairs collagen matura-
tion, which leads to basement membrane aberrations that play a part in glioma 
progression [72]. Taken together, these data show that DNA hypermethylation and 
histone methylation promote tumorigenesis through a wide range of gene function 
changes (Figure 2).
6.3 IDH mutation inducible metabolic alterations
In addition to the epigenetic changes, IDH1 mutation is known to alter hypoxia 
inducible factor 1α (HIF-1α) activity. Under oxidative conditions, α-KG-dependent 
prolyl hydroxylases (PHDs), which form the Egl nine homolog (EglN) families, 
induce HIF-1α hydroxylation. Hydroxylated protein is then bound by the von 
Hippel-Lindau tumor suppressor protein (VHL), ubiquitylated, and degraded via 
proteasome. In contrast, under hypoxia, the hydroxylation reaction is inhibited and 
HIF-1α is upregulated. HIF-1α then activates the transcription of several genes to 
mediate a switch from oxidative to glycolytic metabolism and induces angiogenesis 
by regulating the expression of vascular endothelial growth factor (VEGF) [73, 74]. 
Koivunen et al. [33] demonstrated that IDH1 mutation attenuates HIF-1α through 
the activation of HIF prolyl 4-hydroxylase (EGLN), enhancing the proliferation 
and soft agar growth of NHA.
While several studies demonstrated that the IDH1 mutation induced aerobic 
glycolysis via HIF-1α activity [59, 75], other group reported that HIF-1α responsive 
genes, including lactate dehydrogenase (LDHA) were downregulated; silenced 
LDHA was associated with increased methylation of the LDHA promoter [76]. 
Another group showed that IDH1 mutation reduces pyruvate flux to lactate and 
suppresses monocarboxylate transporters MCT1 and MCT4, which mediate lactate 
transmembrane transport [77]. IDH mutation also alters pyruvate metabolism, 
including pyruvate dehydrogenase and pyruvate carboxylase enzymes, resulting in 
anaplerosis of the TCA cycle [78, 79].
Cancer cells are known to depend on reductive carboxylation (RC) of gluta-
mine-derived α-KG for de novo lipogenesis under hypoxia [80]. It is worth noticing 
Figure 2. 
Biological role of IDH mutation to induce gliomagenesis.
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that the RC pathway is inhibited by IDH mutation [55]. Under hypoxia, IDH1 muta-
tion upregulated the contribution of glutamine to lipogenesis [81, 56].
Altered amino acids, glutathione, choline derivatives, and tricarboxylic acid 
(TCA) cycle intermediates were observed in IDH-mutant cells [82, 83]. Glutamate 
dehydrogenase (GDH)1 and GDH2 were overexpressed in IDH1-mutant tumors, 
and the orthotopic growth of an IDH1-mutant glioma is inhibited by a double 
GDH1/2 knockdown [84]. Another group demonstrated that GDH2 was critical 
for IDH1-mutation induced metabolic alterations and IDH1-mutant glioma growth 
[85]. The presence of 2-HG also inhibited ATP synthase and mTOR signaling [41].
Importantly, branched-chain amino acid transaminase (BCAT), which catalyzes 
the α-KG to glutamate conversion, was expressed at lower levels in IDH1-mutant 
gliomas than in IDH1-wildtype [86, 87]. As a result, the glutamate level was 
decreased, and cell proliferation and invasiveness were suppressed in IDH-mutant 
gliomas [87].
7. Role of extensive resection in IDH1-mutant gliomas
There is a huge amount of evidence showing that surgical resection has a pivotal 
role in survival benefit of glioma patients. Extensive resection is known to prolong 
survival in low grade glioma and also in GBM (IDH1-wildtype) [88–91]. In IDH1-
mutant gliomas, an MRI study demonstrated that IDH1-mutant tumors were rarely 
located in high risk areas of the brain and show unilateral patterns of growth, sharp 
tumor margins, and less contrast enhancement [92, 93]. Indeed, radiographic 
atlas revealed IDH1-mutant gliomas were frequently located at frontal lobe [94]. 
A diffusion-tensor imaging study demonstrated that IDH-mutant GBM has a less 
invasive phenotype than IDH-wildtype GBM [95]. Intriguingly, patients with IDH1-
wildtype gliomas had a reduced neurocognitive function and lower performance 
score than those with IDH1-mutant gliomas [96]. In addition, lesion volume was not 
associated with neurocognitive function for patients with IDH1-mutant tumors, but 
associated for those with IDH1-wildtype tumors [96]. Consequently, IDH1-mutant 
gliomas may be relatively less invasive to the surrounding eloquent area than IDH-
wildtype GBM.
In addition, Beiko et al. [97] reported that extensive resection, including 
nonenhancing area, prolonged survival in IDH1-mutant anaplastic astrocytoma 
and glioblastoma. They also mentioned, since IDH1-mutant gliomas were predomi-
nantly located at frontal lobe, that maximal resection was relatively amenable. 
Another group independently demonstrated that gross total resection extended 
survival in grade III IDH1-mutant gliomas without 1p/19q co-deletion [98]. In con-
trast, survival advantage was controversial in grade II astrocytoma [99, 100]. These 
results suggest that for IDH1-mutant gliomas, especially grade III astrocytoma, 
maximal resection should be considered.
8. Prediction of IDH status
To establish IDH status-based treatment strategies, including surgery, advanced 
preoperative or intraoperative molecular analysis is important. Magnetic reso-
nance spectroscopy (MRS) can be used to detect 2-HG and glutamate changes 
[101–107]. A recent MRS study demonstrated that 2-HG peaks rapidly decrease in 
accordance with tumor regression, whereas they increase with tumor progression 
in IDH-mutant gliomas [108], suggesting that 2-HG concentration, measured by 
MRS, may be a reliable approach to evaluate disease states in IDH-mutant gliomas. 
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In addition, several MR techniques, including diffusion tensor imaging and MR 
methods for determining relative cerebral blood volume, have been proposed 
to detect mutant IDH1 noninvasively [109–111]. Moreover, T2-FLAIR mismatch 
sign was found as a highly specific imaging marker for IDH-mutant astrocytoma 
[112–114]. Intraoperative technologies to assess IDH1 mutation have also been 
established [115–117]. These advanced technologies may allow the development of 
tailored surgical strategies for IDH-mutant gliomas. Other group demonstrated that 
urinary 2-HG is increased in patients with IDH1-mutant gliomas [118]. These find-
ings indicate the possibility of application of indirectly assessed 2-HG as a clinical 
biomarker.
9. Treatment vulnerability in IDH-mutant gliomas
9.1 Radiotherapy for IDH-mutant gliomas
It has been shown that there is a higher relative sensitivity to radiotherapy and 
concurrent temozolomide (TMZ) in IDH1-mutant GBM patients than in those 
with IDH1-wildtype GBM [119], although there is no prospective clinical evidence 
of radiation therapy to extend survival in glioma patients with IDH1 mutation. 
As described above, IDH mutation inhibits NADPH and glutamate production, 
resulting in reduced glutathione levels and increased reactive oxygen species (ROS) 
[120–123]. Conversely, radiosensitivity in IDH1-mutant tumors was diminished by 
IDH1 inhibitor [124]. These findings support selective vulnerability to radiation 
therapy in IDH-mutant gliomas.
9.2 Chemotherapeutic evidence for IDH-mutant gliomas
9.2.1 Temozolomide
Current standard management of GBM consists of surgical tumor resection, 
following local radiotherapy with temozolomide treatment [125]. Additionally, 
adjuvant TMZ prolonged survival in anaplastic astrocytoma [126]. Several studies 
demonstrated IDH1-mutation as a predictive biomarker for TMZ sensitivity in low 
grade gliomas and secondary GBM [127, 128].
Cytotoxicity of TMZ is provoked by the formation of O6-methylguanine (O6G)-
DNA adducts. O6G-DNA adducts induce DNA strand break and apoptosis through 
the O6G-thymine-mediated mismatch repair pathway [129, 130]. It has also been 
established that the activation of DNA repairing pathways, including methylgua-
nine methyltransferase (MGMT) repair enzyme, together with mismatch repair 
(MMR) system proteins deficiency, such as mutation-induced MSH2 and MSH6, 
result in drug resistance [131–133]. MGMT promoter methylation is highly methyl-
ated in IDH1-mutant gliomas, particularly oligodendrogliomas, compared with 
IDH-wildtype [43].
Some preclinical studies demonstrated that forced IDH mutation sensitized cells to 
chemotherapy by increased ROS [134–136]. Conversely, forced IDH1 mutation revealed 
that IDH1 mutation-induced temozolomide (TMZ) resistance and rapid G2 cell cycle 
arrest through increased RAD-51-mediated homologous recombination (HR) [137, 138]. 
Importantly, among DNA adducts, O6G represents less than 10%, while the majority 
of TMZ-induced DNA lesions are N7-methylguanine (60–80%) and N3-methyladenine 
(10–20%) adducts, which are immediately repaired through poly(ADP-ribose)poly-
merase (PARP)-dependent base excision repair (BER) [129, 139, 140]. We have recently 
shown that there are lower steady state NAD+ levels in IDH1-mutant gliomas [141],  
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and that TMZ immediately induces NAD+ consumption through PARP activation-
mediated BER in IDH1-mutant gliomas [142]. Besides, Lu et al. [143] reported that the 
PARP associated DNA repair pathway was extensively compromised in IDH1-mutant 
cells due to decreased NAD+ availability, thus, cells were sensitive to TMZ, suggest-
ing that deregulated NAD+ metabolism may be related with chemosensitivity. Taken 
together, these studies show that IDH mutation may increase susceptibility to chemo-
therapy; however, it remains unclear if IDH mutation itself promotes TMZ sensitivity.
In contrast, TMZ-induced hypermethylation is a critical problem. Long-term 
TMZ exposure induces MMR inactivation, followed by DNA hypermutation 
phenotype. Among numerous mutations, gene alterations in RB and AKT-mTOR 
pathways promoted malignant progression in IDH1-mutant gliomas [27].
9.2.2 Other chemotherapeutic agents
Sulkowski et al. [144] demonstrated that 2-HG inhibits KDM4A and KDM4B, 
histone demethylases that play a critical role in double strand repair. As a result, IDH1 
mutation suppresses HR and induces PARP inhibitor sensitivity. Additionally, IDH1-
mutant downregulates the DNA double strand break sensor ATM by altering histone 
methylation, resulting in impaired DNA repair. As a result, IDH1 mutation causes 
DNA damage susceptibility to radiation and daunorubicin and reduces self-renewal 
of hematopoietic stem cells in acute myeloid leukemia [145].
10. Novel therapeutic target in IDH1-mutant tumors
10.1 Specific IDH inhibitor
In 2013, specific inhibitors for IDH1 and IDH2 mutations were discovered  
[70, 146]. In IDH2-mutant AML cells, an IDH2R140Q inhibitor induced both histone 
and DNA demethylation [147]. These effects reversed blocked cell differentiation 
and resulted in cytotoxicity in vitro [146, 147]. It is interesting to note that histone 
hypermethylation is more rapidly reversed than DNA hypermethylation [147]. In 
IDH1-mutant AML cells, differentiation and DNA demethylation were also induced 
by a next generation IDH1 inhibitor [148]. Since the IDH2 mutation is crucial for 
proliferation and maintenance of leukemia cells [149], an IDH inhibitor may be 
used as a novel and efficient chemotherapeutic agent against IDH-mutant AML 
cells. Indeed, clinical trials demonstrated durable response for IDH1/2-mutant 
refractory AML patients [150, 151].
In IDH1-mutant glioma cells, Rohle et al. [70] reported that a specific IDH1 
inhibitor, AGI-5198, blocked 2-HG production, histone demethylation, cell dif-
ferentiation, and inhibited cell growth in endogenous IDH1-mutant glioma cells. 
Other group demonstrated that BAY 1436032, a pan inhibitor of IDH1 mutation, 
promoted mild cytotoxic effects in vivo [152]. In contrast, we established that, 
even with a long-term IDH1 inhibitor treatment, 2-HG depletion does not induce 
demethylation of global-DNA and histones, cell differentiation, nor cytotoxicity 
[141]. Studies using another IDH1 inhibitor also revealed minimal cytotoxicity 
despite a rapid decrease in 2-HG levels in glioma cells [153, 154]. Similarly, treat-
ment with an IDH1 inhibitor did not contribute to cytotoxicity, and the CpG island 
methylation status as well as histone trimethylation levels were largely retained 
in malignant glioma and chondrosarcoma [155, 156]. Intriguingly, in immortal-
ized human astrocytes with an inducible IDH1R132H expression system, a specific 
IDH1 inhibitor induced demethylation and inhibited tumorigenesis when forced 
expression was prior or concomitant to inhibitor treatment, but these effects were 
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not observed if the treatment was delayed [157]. These results indicate that 2-HG 
depletion or blocked mutant IDH1 might be insufficient to control tumor growth 
and reprogramming of epigenomic alterations in progressed IDH1-mutant gliomas. 
Indeed, preliminary results indicate that the 6-month progression-free survival of 
IDH1-mutant glioma, chondrosarcoma, and cholangiocarcinoma is 25, 56, and 43%, 
respectively, suggesting that the potential of the IDH1 inhibitor may be weaker in 
IDH1-mutant gliomas than in other cancers [158].
10.2 Other treatment strategies
10.2.1 DNA demethylating agents
In addition to IDH1 inhibitor treatments, other strategies to control IDH1-
mutant tumor cells have been proposed. Because the IDH1 mutation promotes 
proliferation by blocking DNA demethylation, treatment with DNA demethylat-
ing agents reverses DNA methylation and inhibits proliferation in IDH1-mutant 
cells [71, 159]. Intriguingly, treatment with both the DNA demethylating agent 
5-azacytidine (5-Aza) and TMZ demonstrated extensively prolonged survival in an 
IDH1-mutant orthotopic xenograft model [160].
10.2.2 Bcl-2 family inhibitors
Since 2-HG suppresses the activity of cytochrome c oxidase in mitochondrial 
complex IV, the mitochondrial threshold for apoptosis was decreased after BCL-2 
inhibition in IDH1 and IDH2-mutant AML [161]. Similarly, another Bcl-2 family 
member, the Bcl-xL inhibitor, induced apoptosis in IDH-mutant cells, including 
endogenous IDH1-mutant glioma cells [162]. Together, inhibition of Bcl-2 family 
members may be targetable to control growth in IDH-mutant cells.
10.2.3 DNA damaging agents
Because PLK1 activation provokes a rapid bypass through the G2 checkpoint 
after TMZ treatment in IDH1-mutant tumors, combination treatments with TMZ 
and a PLK1 inhibitor significantly suppressed tumor growth in an IDH1-mutant in 
vivo model [138]. In tumors with ATRX mutation-associated alternative lengthen-
ing telomeres (ALT), ATR inhibitor is highly sensitive [163], implying that such 
inhibition may be useful for treatments of IDH1-mutant astrocytic tumors with 
positive ALT. IDH1 mutation blocked HR, so-called “BRCA ness” phenotype 
provided specific sensitivity for PARP inhibitor both in vitro and in vivo [144].
10.2.4 DLL-3 targeting therapy
Since Notch ligand DLL-3 is overexpressed in IDH-mutant gliomas, anti-DLL3 
antibody-drug conjugate (ADC), rovalpituzumab tesirine (Rova-T), is a potent 
therapeutic agent for IDH-mutant gliomas [164].
10.2.5 Vaccination therapy
Schumacher et al. [165] reported an immunological approach to control IDH1-
mutant cells. They showed that an epitope derived from the IDH1-mutant amino 
acid sequence is presented in HLA class II molecules of antigen-presenting cells, 
which elicit a strong immune response via CD4 + T cells. In addition, they showed 
that constitutive stimulation with synthetic peptides having the IDH1-mutation 
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sequence developed an immune response that eradicated IDH1 mutated tumors in 
a mouse model with human HLA molecules. Thus, vaccine therapy targeting for 
IDH1-mutation is expected to develop for future clinical trial [165, 166]. Moreover, 
IDH1-mutation caused downregulation of leukocyte chemotaxis, resulting in 
repression of the tumor-associated immune system including immune cells, such 
as macrophages [167]. Additionally, tumor infiltrating lymphocytes (TILs) and 
programmed death ligand 1 (PD-L1) were expressed at low levels in IDH1-mutant 
gliomas [168]. In contrast, Kohanbash et al. [153] demonstrated reduced expression 
of cytotoxic T lymphocyte-associated genes and IFN-gamma inducible chemo-
kines in IDH1-mutant cells; these results were reversed by specific IDH1 inhibitor. 
Therefore, combination treatments with vaccine immunotherapy and IDH1 inhibi-
tor result in enhanced toxicity in IDH-mutant tumors.
10.2.6 Target for altered metabolism
IDH1 mutation induced altered metabolism is also expected as a novel therapeu-
tic target. Based on the fact that the main carbon source for α-KG and 2-HG synthe-
sis in IDH1-mutant cells is glutamine from glutaminolysis, a suitable target therapy 
would be the use of glutaminase (GLS) inhibitor or anti-diabetic drug metformin 
via the inhibition of mitochondrial complex I in the electron transport system 
[83, 169–171]. Since reduced glutamate blocks glutathione synthesis, inhibition of 
glutaminase specifically sensitizes IDH-mutant glioma cells to oxidative stress and 
radiation [86].
Mutant IDH1 alters steady state levels of NAD+ through inhibiting NAPRT1, one 
rate limiting enzyme for NAD+ biosynthesis. Therefore, inhibition of nicotinamide 
phosphoribosyltransferase (NAMPT), another rate limiting enzyme, induced high 
cytotoxicity in IDH1-mutant patient-derived glioma cells [141]. Since TMZ rapidly 
consumes NAD+ through PARP activation, combination treatments with TMZ 
and NAMPT inhibitor further enhanced NAD+ depletion-mediated cytotoxicity 
in IDH1-mutant cancers [142]. Similarly, Lu et al. [143] reported that the PARP-
associated DNA repair pathway was extensively compromised in IDH1-mutant cells 
due to decreased NAD+ availability, thus sensitive to TMZ.
Because of the relationships between IDH1 mutation and MYC activation 
[38, 40, 172], target therapy to regulate MYC, by using bromodomain and 
extra-terminal (BET) inhibitors, CDK7 or MYC-induced glycolysis may be used 
for IDH-mutant gliomas [40, 173–175]. Given the results of these studies, IDH1 
mutation-specific biological alterations and metabolic feature may be expected as 
novel therapeutic targets.
11. Conclusions
In summary, investigations on IDH mutations enabled distinctive tumor clas-
sification and may allow the development of specific therapeutic strategies. Further 
preclinical and clinical studies are warranted to overcome the outcomes of cancer 
development in IDH-mutant glioma patients.
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